Cryoport, Inc. (NASDAQ:CYRX – Get Free Report) shares gapped down prior to trading on Wednesday after Needham & Company LLC lowered their price target on the stock from $19.00 to $18.00. The stock had previously closed at $16.30, but opened at $14.50. Needham & Company LLC currently has a buy rating on the stock. Cryoport shares last traded at $16.13, with a volume of 80,212 shares traded.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in Cryoport by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 3,657,661 shares of the company’s stock worth $56,657,000 after purchasing an additional 98,569 shares during the last quarter. American International Group Inc. raised its position in Cryoport by 6.9% in the 4th quarter. American International Group Inc. now owns 21,512 shares of the company’s stock worth $333,000 after purchasing an additional 1,386 shares during the last quarter. Sierra Summit Advisors LLC bought a new stake in shares of Cryoport during the 4th quarter valued at $665,000. Barclays PLC raised its position in shares of Cryoport by 337.5% during the 4th quarter. Barclays PLC now owns 72,103 shares of the company’s stock valued at $1,117,000 after acquiring an additional 55,624 shares during the last quarter. Finally, Needham Investment Management LLC raised its position in shares of Cryoport by 36.4% during the 4th quarter. Needham Investment Management LLC now owns 225,000 shares of the company’s stock valued at $3,485,000 after acquiring an additional 60,000 shares during the last quarter. Institutional investors own 92.90% of the company’s stock.
Cryoport Stock Down 1.8 %
The firm’s 50-day simple moving average is $15.68 and its 200 day simple moving average is $14.19. The company has a market cap of $783.36 million, a P/E ratio of -14.42 and a beta of 1.61. The company has a debt-to-equity ratio of 0.74, a quick ratio of 11.58 and a current ratio of 12.23.
About Cryoport
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments: Global Logistics Solutions and Global Bioservices. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.